The technology uses the combined expression of genes for two types of potent immune stimulants, cytokines and superantigens, delivered by a variety of vectors. Genes for antigenic proteins from infectious organisms, or the proteins themselves, may be combined with the cytokine and/or superantigen genes to generate an immune response against various infectious diseases.
Advantages of Invention:
* Combined effects of selected compounds yield better results than single compounds
* A single therapeutic composition may have efficacy against multiple cancer types or infectious diseases
* Composition favors development of a Th1-type immune response, triggering cellular immune response in addition to humoral immune response
* Use of superantigen gene triggers immune response at very low dosages, but use of nucleic acid to express superantigen locally minimizes risk of systemic toxicity
State of Development:
Technology has been successfully tested in mice and dogs with several cancer types. Phase I/IIa clinical trials in human melanoma patients were conducted. Enhanced immune response using prototype DNA vaccine has been demonstrated in vivo.
Posts
No comments:
Post a Comment